Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine2c receptor agonist for the treatment of obesity: role of metabolic activation

scientific article published on 7 March 2007

Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine2c receptor agonist for the treatment of obesity: role of metabolic activation is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1124/DMD.106.013649
P698PubMed publication ID17344339
P5875ResearchGate publication ID6463161

P2093author name stringAmit S Kalgutkar
Tristan S Maurer
Phoebe Chiang
Jiri Aubrecht
Richard V Coelho
Evan B Smith
Stephanie L Coffing
Chandra Vage
Klaas Schildknegt
Deepak K Dalvie
Kim F McClure
Jennifer R Cheung
Victor F Soliman
Mary E Lame
P433issue6
P921main subjectobesityQ12174
genotoxicityQ1009245
P304page(s)848-858
P577publication date2007-03-07
P1433published inDrug Metabolism and DispositionQ1261140
P1476titleGenotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine2c receptor agonist for the treatment of obesity: role of metabolic activation
P478volume35

Reverse relations

cites work (P2860)
Q347665385-HT2C ligands: recent progress
Q37950014A review of the use of in silico methods to predict the chemistry of molecular initiating events related to drug toxicity
Q38218540Biotransformation and bioactivation reactions of alicyclic amines in drug molecules
Q89993903Chemicals and Drugs Forming Reactive Quinone and Quinone Imine Metabolites
Q37802740Deleterious Effects of Reactive Metabolites
Q39768889Discovery and development of 5-HT(₂C) receptor agonists for obesity: is there light at the end of the tunnel?
Q46240693Evaluation of chemically diverse 5-HT₂c receptor agonists on behaviours motivated by food and nicotine and on side effect profiles
Q85015974Handling reactive metabolite positives in drug discovery: What has retrospective structure–toxicity analyses taught us?
Q56115898Metabolism-guided drug design
Q36805380Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents
Q44430233Structural identification of imatinib cyanide adducts by mass spectrometry and elucidation of bioactivation pathway
Q91749643Targeting the 5-HT2C Receptor in Biological Context and the Current State of 5-HT2C Receptor Ligand Development
Q38177342Toxicophores, reactive metabolites and drug safety: when is it a cause for concern?
Q35823591We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders.

Search more.